O’Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002;87:933–937.
Neuss MN, Polovich M, McNiff K, . 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. Oncol Nurs Forum 2013;40:225–233.
- Search Google Scholar
- Export Citation
)| false . , Neuss MN , Polovich M , McNiff K 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. 2013; 40: 225– 233. 10.1188/13.ONF.40-03AP2
Borner M, Scheithauer W, Twelves C, . Answering patients’ needs: oral alternatives to intravenous therapy. Oncologist 2001;6(Suppl 4):12–16.
Eek D, Krohe M, Mazar I, . Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence 2016;10:1609–1621.
Given BA, Spoelstra SL, Grant M. The challenges of oral agents as antineoplastic treatments. Semin Oncol Nurs 2011;27:93–103.
Banna GL, Collovà E, Gebbia V, . Anticancer oral therapy: emerging related issues. Cancer Treat Rev 2010;36:595–605.
Cardoso G, Graca J, Klut C, . Depression and anxiety symptoms following cancer diagnosis: a cross-sectional study. Psychol Health Med 2016;21:562–570.
Kristensen A, Solheim TS, Amundsen T, . Measurement of health-related quality of life during chemotherapy—the importance of timing. Acta Oncol 2017;56:737–745.
Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health Syst Pharm 2007;64(Suppl):S4–7.
Bedell CH. A changing paradigm for cancer treatment: the advent of new oral chemotherapy agents. Clin J Oncol Nurs 2003;7(Suppl):5–9.
Berry DL, Blonquist TM, Hong F, . Self-reported adherence to oral cancer therapy: relationships with symptom distress, depression, and personal characteristics. Patient Prefer Adherence 2015;9:1587–1592.
Cheville AL, Alberts SR, Rummans TA, . Improving adherence to cancer treatment by addressing quality of life in patients with advanced gastrointestinal cancers. J Pain Symptom Manage 2015;50:321–327.
Mathes T, Antoine SL, Pieper D, . Adherence enhancing interventions for oral anticancer agents: a systematic review. Cancer Treat Rev 2014;40:102–108.
Jacobs JM, Pensak NA, Sporn NJ, . Treatment satisfaction and adherence to oral chemotherapy in patients with cancer. J Oncol Pract 2017;13:e474–485.
Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther 1999;21:1074–1090, discussion 1073.
Cella DF, Tulsky DS, Gray G, . The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570–579.
Cleeland CS, Mendoza TR, Wang XS, . Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 2000;89:1634–1646.
Peipert JD, Beaumont JL, Bode R, . Development and validation of the functional assessment of chronic illness therapy treatment satisfaction (FACIT TS) measures. [Erratum in Qual Life Res 2014; 23:1907.] Qual Life Res 2014;23:815–824.
Zimet GD, Dahlem NW, Zimet SG, . The multidimensional scale of perceived social support. J Pers Assess 1988;52:30–41.
Mendoza TR, Wang XS, Cleeland CS, . The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999;85:1186–1196.
Krolop L, Ko YD, Schwindt PF, . Adherence management for patients with cancer taking capecitabine: a prospective two-arm cohort study. BMJ Open 2013;3:e003139.
Mackler E, Beekman K, Bushey L, . Utilizing patient reported outcomes for patients receiving oral chemotherapy [abstract]. J Clin Oncol 2017;35(Suppl):Abstract 190.
Brucker PS, Yost K, Cashy J, . General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof 2005;28:192–211.
Greer JA, Amoyal N, Nisotel L, . A systematic review of adherence to oral antineoplastic therapies. Oncologist 2016;21:354–376.
Weingart SN, Li JW, Zhu J, . US cancer center implementation of ASCO/Oncology Nursing Society chemotherapy administration safety standards. J Oncol Pract 2012;8:7–12.
Fishbein JN, Nisotel LE, MacDonald JJ, . Mobile application to promote adherence to oral chemotherapy and symptom management: a protocol for design and development. JMIR Res Protoc 2017;6:e62.
Hofman M, Ryan JL, Figueroa-Moseley CD, . Cancer-related fatigue: the scale of the problem. Oncologist 2007;12(Suppl 1):4–10.
Zabora J, BrintzenhofeSzoc K, Curbow B, The prevalence of psychological distress by cancer site. Psychooncology 2001;10:19–28.
Kopec JA, Yothers G, Ganz PA, . Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project trial C-06. J Clin Oncol 2007;25:424–430.
- Search Google Scholar
- Export Citation
)| false . , Kopec JA , Yothers G , Ganz PA Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project trial C-06. 2007; 25: 424– 430. 10.1200/JCO.2005.05.2597 17264338
Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med 1992;35:1505–1509.
Stark D, Kiely M, Smith A, . Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 2002;20:3137–3148.